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Abstract
Background: Cleft lip and/or palate (CL/P) increase mortality and morbidity risks for affected infants especially in
less developed countries. This study aimed at assessing the effects of systematic pediatric care on neonatal
mortality and hospitalizations of infants with cleft lip and/or palate (CL/P) in South America.
Methods: The intervention group included live-born infants with isolated or associated CL/P in 47 hospitals
between 2003 and 2005. The control group included live-born infants with CL/P between 2001 and 2002 in the
same hospitals. The intervention group received systematic pediatric care between the 7
th and 28
th day of life. The
primary outcomes were mortality between the 7
th and 28
th day of life and hospitalization days in this period
among survivors adjusted for relevant baseline covariates.
Results: There were no significant mortality differences between the intervention and control groups. However,
surviving infants with associated CL/P in the intervention group had fewer hospitalization days by about six days
compared to the associated control group.
Conclusions: Early systematic pediatric care may significantly reduce neonatal hospitalizations of infants with CL/P
and additional birth defects in South America. Given the large healthcare and financial burden of CL/P on affected
families and the relatively low cost of systematic pediatric care, improving access to such care may be a cost-
effective public policy intervention.
Trial Registration: ClinicalTrials.gov: NCT00097149
Background
Cleft lip and/or palate (CL/P) are common and burden-
some birth defects, occurring in about 1 in 700 births,
with variation by ethnicity and socioeconomic status [1].
CL/P occur in isolation or in association with other birth
defects. The isolated forms are a result of a complex etiol-
ogy of genetic and environmental factors [2-8] The asso-
ciated forms occur due to various etiologies involving
more than 500 Mendelian disorders, chromosome anoma-
lies, teratogens and uncategorized syndromes [9]. CL/P
may result in significant early life problems including
feeding problems, surgery-related events, airway manage-
ment and infections [10]. These complications increase
early life mortality risk, particularly in associated forms
[10-14]. CL/P are among the most common birth defects,
and neonatal mortality from birth defects is a significant
impediment to reducing under-five mortality as part of the
Millennium Development Goals effort [15]. Further, CL/P
significantly increase hospitalization use and costs during
early life and childhood [16,17]. In the United States (US),
first-year inpatient healthcare expenditures for infants
with CL/P are about five times higher than unaffected
children, with higher expenditures by more than eight
times among associated compared to isolated cases [17].
CL/P also increase total healthcare expenditures during
the first ten years of life by about eight times [16]. In
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any medium, provided the original work is properly cited.addition to these early-life impacts, CL/P increase the risks
of mortality [18], mental health problems [19] and certain
cancers [20] later in life. CL/P may reduce the quality of
life of affected individuals and families [21] in both isolated
and associated cases and result in psychological and social
adjustment problems [22-25].
Systematic pediatric care plays a key role in addressing
the early life complications of CL/P. Access to such care
during the neonatal period is critical for identifying and
treating complications and educating parents in feeding
and other care practices. There have been no large-scale
studies of CL/P impacts on mortality and hospitalizations
in less developed countries and of the effects of systematic
pediatric care on these risks. This study assesses the effects
of a systematic pediatric care program on neonatal mortal-
ity and hospitalizations of infants with CL/P in South
America. The study background and methods have been
described in greater detail elsewhere [26]. This paper
reports the intervention effects on mortality and hospitali-
zation use.
Methods
Setting and Participants
The study intervention population included a consecutive
series of in-hospital live-born infants with any form of
isolated or associated typical CL/P, between January 1,
2003 and December 31, 2005 in 47 hospitals in Argen-
tina, Brazil, Bolivia, Chile, Colombia, Ecuador and Vene-
zuela [26]. The isolated group had no other major birth
defects besides CL/P and no syndromes including those
with or without chromosomal abnormalities. Pierre-
Robin was considered as isolated cleft palate. Associated
cases were identified using physical exams and medical
expert review [27]. The control population included all
infants with typical CL/P born between January 1, 2001
and December 31, 2002 in the same study hospitals as
the intervention group. The same definitions for isolated
and associated status were used for the treatment and
control groups. Table 1 reports the distribution of the
other birth defects in the associated treatment and con-
trol groups. The investigators considered randomizing
the prospectively enrolled group into control and inter-
vention groups to be unethical given that the study’s
intervention represents the standard of care in developed
countries such as the United States, where early and reg-
ular evaluation of infants with oral clefts within the neo-
natal period is emphasized [28].
The study hospitals were affiliated with the Latin
American Collaborative Study of Congenital Malforma-
tions (ECLAMC), which is a birth defect surveillance
and research program throughout South America [29].
ECLAMC involves collaboration with pediatricians who
monitor birth defect occurrence in their hospitals and
collect birth record data on affected and unaffected
infants. The ECLAMC pediatricians were responsible for
identifying and enrolling infants into the study and pro-
viding the intervention.
The intervention sample included 663 infants enrolled
within 48 hours after birth and before hospital dis-
charge. The sample represents 94% of eligible potential
subjects (707 cases). The other potential subjects did
not consent to the study. Parental consent was obtained
from each child’s parent(s) before participation.
The control sample included 456 infants who represent
91% of potential control subjects (499 cases). The non-
intervened control group had received the medical care
available in the community, which is unmeasured but is
thought to vary between the various communities
included in the study and to be less intensive and systema-
tic on average than the study intervention. The study
pediatricians identified the control group from the
ECLAMC and hospital birth records and conducted
phone and/or in-person interviews with parents to obtain
data on infant survival and hospitalizations. The pediatri-
cians also abstracted related information from the infants’
hospital charts.
As described below, the intervention started at the 7
th
day of life. Therefore, all infants who died before the 7
th
day were excluded from the analysis as they had not
received the intervention as defined in the protocol,
resulting in a final sample of 543 infants in the interven-
tion group and 372 controls for the survival analysis.
Table 2 presents a comparison of baseline health and
other relevant characteristics between the study popula-
tions and enrolled samples by intervention status. There
were no statistically significant differences between the
study populations and samples, suggesting no sample
selection bias due to parental consenting into the study.
The sample is geographically and socioeconomically
diverse, which enhances its representativeness of the
infant populations in the study countries. The majority of
infants in the study countries are thought to be born in
healthcare institutions [30]. The WHO reports that rates
of births attended by skilled health personnel, most of
which are expected to have occurred in healthcare insti-
tutions, ranged from about 61% in Bolivia to ~100% in
Chile in 2003-2005 [31]. The study results are generaliz-
able to in-hospital born infants, who represent the major-
ity of infants in the study populations.
The study was approved by the University of Iowa IRB
(protocol ID 200109029).
Neonatal Pediatric Care Intervention
The intervention consisted of four weekly visits with the
study pediatricians between the 7
th and 28
th day of life
which involved systematic evaluation of the infant’s health,
providing pediatric care, referral to specialized care as
needed and educating parents in feeding practices and
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screened infants for eligibility and enrolled those who are
eligible into the study within the first 48 hours and before
hospital discharge. As part of this screening, the pediatri-
cians advised mothers about needed healthcare and opti-
mal feeding and homecare practices following ECLAMC’S
routine ORIENT program, which provides affected
families with cleft- related information and orients them
to available healthcare resources [29]. The control families
had also received the ORIENT program information at
this period.
Once a week, the study pediatricians monitored and
assessed the health of the intervention group infants dur-
ing in-person visits to the pediatricians’ practices. The
pediatricians conducted home visits when possible with
families who missed the weekly visits. The pediatricians
evaluated changes in weight, length, head circumference,
feeding methods and medical complications such as
hyperbilirubinemia or infection. After the examination,
the pediatricians referred the infants for further
intervention to specialized professionals as needed. The
pediatricians assessed the need for hospitalizing infants
who showed no weight gain between visits and for more
frequent follow-up than the weekly visit schedule for
these infants or infants with other medical complications.
The study protocol required the pediatricians to hospita-
l i z ei n f a n t sw h os h o wm o r et h a nt e np e r c e n tw e i g h t
decrease between visits and to evaluate the need for hos-
pitalizing infants with ten percent or less weight decrease
based on the infant’s health, medical complications and
standard pediatric judgment. The study protocol required
the pediatricians to re-emphasize at each visit the recom-
mendations and instructions to parents on feeding prac-
tices and optimal homecare. The control group did not
receive the weekly pediatric visits provided to the inter-
vention group.
Study Outcome Measures
The study assessed the intervention effect on neonatal
mortality between the 7
th and 28
th d a yo fl i f ea n do n
Table 1 Distribution of Birth Defects in the Treatment and Control Associated Groups
Birth Defect Type Control group Treatment group Total study sample
Frequency Percent Frequency Percent Frequency Percent
Abdominal wall defect 7 1.88 5 1.04 12 1.40
Anencephaly 9 2.41 5 1.04 14 1.64
Spina bifida 4 1.07 2 0.41 6 0.70
Brain defect 28 7.51 41 8.49 69 8.06
Cephalocele 3 0.80 8 1.66 11 1.29
Eye anomaly 14 3.75 22 4.55 36 4.21
Microtia 10 2.68 23 4.76 33 3.86
Congenital heart defect 32 8.58 48 9.94 80 9.35
Lung hypoplasia 1 0.27 2 0.41 3 0.35
Esophageal atresia 3 0.80 4 0.83 7 0.82
Gut anomaly 2 0.54 3 0.62 5 0.58
Genitalia defect 13 3.49 15 3.11 28 3.27
Kidney defect 7 1.88 23 4.76 30 3.50
Talipes 27 7.24 31 6.42 58 6.78
Polydactyly 26 6.97 17 3.52 43 5.02
Syndactyly 10 2.68 8 1.66 18 2.10
Limb reduction defect 7 1.88 17 3.52 24 2.80
Hip dislocation 1 0.27 2 0.41 3 0.35
Arthrogryposis 7 1.88 4 0.83 11 1.29
Axial defect 10 2.68 3 0.62 13 1.52
Hydrops 2 0.54 0 0.00 2 0.23
Situs inversus 1 0.27 0 0.00 1 0.12
Syndromes 24 6.43 17 3.52 41 4.79
Minor anomalies 90 24.13 143 29.61 233 27.22
Other anomalies 35 9.38 40 8.28 75 8.76
The Table reports the distribution of all the other birth defects besides CL/P observed in the associated cases. Minor anomalies angioma, neonatal tooth, gum/
tongue anomaly, undescended testes, nevus, micorgnathia and other minor anomalies. Other anomalies include other eye anomalies, anomalies of the neck,
nose, trachea, skull shape and muscle. Also included are other unspecified birth defects (1 birth defect in the control group and 17 birth defects in the treatment
group). The distributions of birth defect types between the treatment and control groups are different at p = 0.027 based on a chi-square test of independence.
However, the test result should be viewed with caution given the very low frequencies of several birth defect types.
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infants, both pooling and stratifying by CL/P associated
status. These outcomes were measured beginning on the
7
th day of life given that the pediatric intervention
started on that day. We also report the overall neonatal
mortality rates between the first and 28
th day of life
given that such estimates are rare in South America.
The study pediatricians assessed survival and hospitali-
zations using the same study questionnaires at all hospi-
tals during their visits with the intervention group and
interviews with the control group. Further details of
data collection and management are described elsewhere
[26].
Statistical Analysis
Given the non-randomized design of the study, we
assessed the intervention effects on the study outcomes
adjusting for relevant baseline characteristics including
infant’s cleft type (cleft lip, cleft palate, cleft lip with
palate), birth weight, gestational age, sex and ethnic
Table 2 Distribution of Study Variables in the Population and Study Samples by Intervention Group
Variable Control Group Intervention Group
Population Total
Sample
Sub-sample with Mortality
Outcome
Population Total
Sample
Sub-sample with Mortality
Outcome
Overall Sample Size 499 456 441 707 663 602
Maternal Age 25.78 (6.89) 25.77 (6.94) 25.79 (6.89) 26.37 (6.92) 26.30 (6.86) 26.29 (6.86)
Number of prenatal visits 5.58 (3.01) 5.65 (2.95) 5.66 (2.94) 4.51 (3.51) 4.56 (3.51) 4.67 (3.51)
Maternal chronic illness (N) 469 431 419 702 659 598
No (%) 395(84.2) 358 (83.1) 347 (82.8) 548 (78.1) 516 (78.3) 471 (78.8)
Yes (%) 74(15.8) 73 (16.9) 72 (17.2) 154 (21.9) 143 (21.7) 127 (21.2)
Ethnic Ancestry (N) 465 427 416 691 652 592
Black (%) 51(11.0) 51 (11.9) 50 (12.0) 81 (11.7) 77 (11.8) 68 (11.5)
Native (%) 348(74.8) 313 (73.3) 303 (72.8) 523 (75.7) 492 (75.5) 449 (75.8)
Other (%) 66(14.2) 63 (14.8) 63 (15.1) 87 (12.6) 83 (12.7) 75 (12.7)
Birth weight (grams) 2887.5
(788.5)
2,863.5
(797.8)
2870.8 (803.7) 2881.9
(740.3)
2,892.9
(726.7)
2871.3 (732.2)
Gestational age (weeks) 38.3 (3.4) 38.3 (3.4) 38.3 (3.5) 38.5 (3.1) 38.5 (3.1) 38.4 (3.2)
Time of cleft diagnosis (N) 495 454 439 701 657 596
Prenatal (%) 80 (16.2) 76 (16.7) 73 (16.6) 174 (24.8) 161 (24.5) 145 (24.3)
Other (%) 415(83.8) 378 (83.3) 366 (83.4) 527 (75.2) 496 (75.5) 451 (75.7)
Sex (N) 491 450 437 705 661 601
Male (%) 275(56.0) 250 (55.6) 245 (56.1) 394 (55.9) 372 (56.3) 338 (56.2)
Female (%) 216(44.0) 200 (44.4) 192 (43.9) 311 (44.1) 289 (43.7) 263 (43.8)
Multiple birth (N) 496 455 440 707 663 602
No (%) 484(97.6) 443 (97.4) 428 (97.3) 688 (97.3) 646 (97.4) 586 (97.3)
Yes (%) 12 (2.4) 12 ( 2.6) 12 (2.7) 19 (2.7) 17 ( 2.6) 16 (2.7)
Associated Status (N) 499 456 441 707 663 602
Isolated (%) 361(72.3) 325 (71.3) 313 (71.0) 478 (67.6) 451 (68.0) 405 (67.3)
Associated (%) 138(27.7) 131 (28.7) 128 (29.0) 229 (32.4) 212 (32.0) 197 (32.7)
Type of Cleft (N) 496 455 441 706 663 602
Palate only (%) 129(26.0) 121 (26.6) 118 (26.8) 197(27.9) 181 (27.3) 163 (27.1)
Lip only (%) 87(17.5) 77 (16.9) 75 (17.0) 120(17.0) 111 (16.7) 101 (16.8)
Lip and Palate (%) 280(56.5) 257 (56.5) 248 (56.2) 389(55.1) 371 (56.0) 338 (56.2)
Type of Delivery (N) 492 451 436 707 663 602
Cesarean (%) 184(37.4) 168 (37.3) 163 (37.4) 280(39.6) 258 (38.9) 238 (39.5)
Other (%) 308 (62.6) 283 (62.7) 273 (62.6) 427 (60.4) 405 (61.1) 364 (60.5)
The Table includes the distribution of study variables in the study population, study sample and sample with mortality data. Means and standard deviations (in
parentheses) are reported for continuous variables. Counts and percentages (in parentheses) are reported for categorical variables.
The following comparisons were examined within each of the intervention and control groups: 1) population versus study sample and 2) study sample versus
sample with mortality data.
The differences in the number of observations in the subsamples with mortality outcome in this table and those included in mortality analysis in Table 1i sd u e
to limiting the mortality analysis to those who were alive on the 7
th day after birth. The subsamples with mortality outcome in Table 6 include all consented
infants with known mortality outcome including those who died before the 7
th day of life since the goal is to check for any characteristics that are related to
dropping out of the study resulting in unknown mortality status.
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nal chronic illness, multiple birth status, cesarean-deliv-
ery and prenatal CL/P diagnosis. The regression models
included country fixed effects in order to account for
country differences. As a reference, we also estimated
regressions that did not adjust for baseline characteristics
but only included the treatment and country indicators.
ECLAMC pediatricians routinely measure these baseline
characteristics through interviews with the mothers after
delivery and before hospital discharge and through hospi-
tal record abstraction. Table 3 describes the baseline
characteristics in the study intervention and control
groups. There were no significant differences in these
characteristics between the intervention and control
groups except for a greater number of prenatal visits and
greater birth weight among the isolated control group,
Table 3 Distribution of Baseline Characteristics in the Intervention and Control Groups Included in the Mortality
Analysis
Overall Isolated Associated
Variable Intervention
N = 543
Control
N = 372
Intervention N = 394 Control
N = 305
Intervention
N = 149
Control
N=6 7
Maternal Age 26.23
(6.83)
25.50
(6.67)
25.88 (6.58) 25.40 (6.53) 27.14 (7.39) 25.92 (7.30)
Number of prenatal visits 4.74***
(3.54)
5.87
(2.91)
4.47*** (3.56) 5.95 (2.87) 5.47 (3.39) 5.51
(3.09)
Maternal chronic illness
No (%) 425 (78.7) 291(82.4) 315 (80.6) 237(82.6) 110 (73.8) 54(81.8)
Yes (%) 115 (21.3) 62 (17.6) 76 (19.4) 50 (17.4) 39 (26.2) 12(18.2)
Ethnic Ancestry
Black (%) 57(10.7) 31 (8.8) 41 (10.5) 26 (9.1) 16 (11.0) 5 (7.7)
Native American (%) 407 (76.3) 262(74.4) 296 (76.1) 209(72.8) 111 (76.6) 53(71.5)
Other (%) 70 (13.1) 59 (16.8) 52 (13.4) 52 (18.1) 18 (12.4) 7 (10.7)
Birth weight (grams) 2,976.7*
(648.6)
3,046.6
(670.3)
(797.75)
3,031.9** (618.1) 3,123.8 (631.0) 2,831.0 (704.8) 2,694.8 (733.5)
Gestational age (weeks) 38.75
(2.86)
38.92
(2.74)
38.89* (2.80) 39.19 (2.51) 38.38 (2.97) 37.71 (3.37)
Time of cleft diagnosis
Prenatal (%) 116 (21.6) *** 38 (10.3) 64 (16.4)*** 24 (7.9) 52 (35.4)** 14(21.2)
Other (%) 421 (78.4) 332(89.7) 326 (83.6) 280(92.1) 95 (64.6) 52 (78.8)
Sex
Male (%) 307 (57.3) 213(57.3) 222 (56.4) 178(58.4) 85 (57.1) 35(52.2)
Female (%) 236 (43.5) 159(42.7) 172 (43.7) 127(41.6) 64 (43.0) 32(47.8)
Multiple birth
No (%) 529 (97.4) 361(97.3) 381(96.7) 295(97.0) 148 (99.3) 66 (98.5)
Yes (%) 14 ( 2.6) 10 (2.7) 13 (3.3) 9 (3.0) 1 (0.7) 1 (1.5)
Associated Status
Isolated (%) 394 (72.6) 305(82.0) - - - -
Associated (%) 149 (27.4) 67 (18.0) - - - -
Type of Cleft
Palate only (%) 142 (26.2) 92 (24.7) 83 (21.1) 66 (21.6) 59 (39.6) 26(38.8)
Lip only (%) 96 (17.7) 67 (18.0) 88 (22.3) 60 (19.7) 8 (5.4) 7 (10.5)
Lip and Palate (%) 305 (56.2) 213(57.3) 223 (56.6) 179(58.7) 82 (55.0) 34(50.8)
Type of Delivery
Cesarean (%) 202 (37.2) 127(34.5) 132 (33.5) 94 (31.2) 70 (47.0) 33(49.3)
Other 341(62.8) 241(65.5) 262(66.5) 207(68.8) 79 (53.0) 34(50.8)
The Table includes the distribution of study variables in the study intervention and control groups that are included in the mortality analysis. Means and
standard deviations (in parentheses) are reported for continuous variables. Counts of observations and percentages (in parentheses) are reported for categorical
variables. Significant differences between intervention and control groups are indicated with * at p < 0.1, ** at p < 0.05 and *** at p < 0.01.
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isolated intervention group.
The mortality outcome model was estimated by logistic
regression. The hospitalization day model was estimated
by zero-inflated negative binomial regression in order to
account for the large percentage of zero hospitalizations.
The variance-covariance matrices were estimated with a
Huber-type estimator that is robust for within-hospital
clustering [32].
The intervention effects were estimated pooling and
stratifying by CL/P associated status given the expected
effect differences by the presence of other birth defects.
The models for total and associated samples included the
number of birth defects other than CL/P as a covariate in
order to account for the severity of associated status.
About 6.8% of the sample were lost to follow-up and
had no observable mortality outcomes. Table 2 presents a
comparison between the enrolled sample and the sample
with known mortality status. There were no significant dif-
ferences in baseline characteristics between these samples
for both the intervention and control groups, suggesting
no sample selection bias. Therefore, we did not adjust the
mortality and hospitalization models for sample selection.
Results
Neonatal Mortality
Table 4 reports the mortality rates between the 7
th and
28
th day in the intervention and control groups and the
odds ratios (ORs) for the intervention effect from the
logistic regression. Table 5 reports the ORs for all model
variables.
There were no significant differences in the 7
th-28
th day
mortality rates between the intervention and control
groups, both pooled and stratified by associated status. In
the total sample, the mortality rate was 6.1% in the inter-
vention group versus 4.8% in the control group. In the
isolated group, the mortality rates were 2% versus 1.3% in
the intervention versus control groups, respectively. In
the associated group, the mortality rates were 16.8% ver-
sus 20.9% in the intervention and control groups,
respectively.
The overall neonatal mortality rates between the first
and 28
th day of life were 15.3% and 19.7% in the inter-
vention and control groups, respectively. The overall
neonatal mortality rates were 4.7% and 3.8% in the iso-
lated intervention and control groups, respectively, and
37.1% and 58.6% in the associated intervention and con-
trol groups, respectively.
Neonatal Hospitalization Days
Table 6 reports hospitalization days and the intervention
effects on hospitalization days between the 7
th and 28
th
days of life among the infants who survived the neonatal
period. Table 7 reports the effects of all model variables.
The intervention group had fewer neonatal hospitaliza-
tion days on average compared to the control group (1.9
versus 3.1 days). In the multivariate model, the interven-
tion reduced hospitalization days by about 0.6 days in the
total sample (p = 0.089). There was no significant differ-
ence in hospitalization days between the isolated interven-
tion and control groups (1.6 versus 1.9 days, respectively).
In contrast, there were significantly fewer hospitalization
days in the intervention group with associated CL/P com-
pared to the control group (3.4 versus 10.3 days, respec-
tively). In the multivariate model, the intervention reduced
hospitalization days in the associated group by about 6
days (p < 0.001).
Table 8 reports the distribution of reasons for hospital
readmission for the treatment group; data is not available
on hospital readmission reasons for the control group.
About 18% of readmissions were due to respiratory pro-
blems and 16% were due to weight loss problems. About
12% were due to feeding or nutrition problems. Another
10% were due to surgery including cleft repair or any
other surgery, and another 10% were due to icterus
syndromes.
Effects of Baseline Factors on Mortality and
Hospitalizations
We describe below the significant effects of main baseline
infant and maternal characteristics on mortality and hos-
pitalization days between the 7
th and 28
th day of life (see
detailed results in Tables 5 and 7). African and native
infant ancestry, as reported by the mother, increased
mortality risk by about 32 and 22 times in the total sam-
ple, respectively, compared to other ancestries. Prenatal
CL/P diagnosis decreased mortality risk by about 0.1
times in the isolated group (marginally significant).
Higher birth weight reduced mortality significantly both
pooling and stratifying by associated status - a 300-gram
birth weight decreased mortality risk by about 0.7 times
in the total sample. In the isolated group, infants with
Table 4 Mortality between 7
th and 28
th day in the in
intervention and control groups
Group Mortality Rate (%) Effect of Intervention (Odds
Ratio)
Intervention Control Unadjusted Adjusted
Overall Sample 6.08 4.84 1.28
[0.71,2.32]
1.17
[0.43,3.23]
Isolated 2.03 1.31 1.48
[0.49,4.49]
2.34
[0.64,8.64]
Associated 16.78 20.90 0.76
[0.36,1.61]
0.96
[0.34,2.66]
The Table reports the neonatal mortality rates in the study intervention and
control groups and the odds ratios for the intervention effects on mortality.
The unadjusted model includes indicators for the country of birth as
covariates. The 95% confidence intervals (CI) of the odds ratios are in
brackets.
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risks by about 7.6 and 6.7 times, respectively, compared
to infants with cleft palate only. Finally, the number of
other malformations besides CL/P increased mortality
risk in the associated group by 1.5 times per
malformation.
Table 5 Odds Ratios for the Effects of the Intervention and Baseline Characteristics on Mortality between the 7
th and
28
th day
Total Sample Isolated Sample Associated Sample
Study intervention group 1.28
[0.71,2.32]
1.17
[0.43,3.23]
1.48
[0.49,4.49]
2.34
[0.64,8.64]
0.76
[0.36,1.61]
0.96
[0.34,2.66]
Bolivia 2.64*** 5.98*** 4.70*** 5.54 12.61*** 7.48***
[1.59,4.37] [2.23,16.04] [1.48,14.91] [0.51,59.72] [6.41,24.78] [2.25,24.88]
Brazil 1.17 0.98 1.54 1.69 0.89 2.46
[0.50,2.76] [0.28,3.39] [0.30,7.92] [0.20,13.96] [0.33,2.46] [0.60,10.21]
Chile 0.58 0.45 0.51 0.35 0.46 0.53
[0.21,1.61] [0.13,1.52] [0.06,4.24] [0.02,6.37] [0.16,1.35] [0.14,2.02]
Colombia 1.34 1.46 1.65 0.27 2.33** 4.75
[0.68,2.63] [0.46,4.63] [0.26,10.59] [0.03,2.72] [1.07,5.04] [0.69,32.76]
Ecuador 0.61 3.27* 0.74 1.36 1.13 4.00*
[0.27,1.34] [0.97,10.95] [0.07,7.68] [0.03,73.00] [0.42,3.04] [0.88,18.24]
Venezuela 1.79** 1.44 3.56** 1.45 2.18** 3.69*
[1.08,2.96] [0.42,4.98] [1.10,11.55] [0.28,7.58] [1.15,4.16] [0.78,17.44]
Maternal age (years) 0.99 1.02 0.98
[0.94,1.04] [0.87,1.20] [0.93,1.03]
Number of prenatal visits 1.00 0.97 0.98
[0.86,1.16] [0.68,1.40] [0.85,1.12]
Maternal chronic illnesses 0.78 0.31 1.08
[0.34,1.78] [0.02,5.71] [0.44,2.62]
African ancestry 32.19*** 7.74*
[2.53,410.06] [0.81,73.92]
Native ancestry 22.03** 2.39 4.41**
[1.61,302.34] [0.18,32.35] [1.42,13.74]
Prenatal diagnosis of cleft 0.79 0.09* 0.77
[0.24,2.59] [0.01,1.50] [0.25,2.38]
Associated status 6.60***
[1.88,23.25]
Birth weight (gm) 0.998*** 0.998*** 0.999**
[0.998,0.999] [0.997,0.999] [0.998,0.999]
Gestational age (weeks) 0.92 0.78* 0.99
[0.80,1.07] [0.60,1.00] [0.84,1.17]
Female 0.83 0.96 1.09
[0.38,1.85] [0.19,4.94] [0.39,3.07]
Multiple birth 0.22* 0.32
[0.05,1.05] [0.04,2.50]
Cleft lip only 1.26 7.63* 0.77
[0.42,3.83] [0.95,61.23] [0.14,4.25]
Cleft lip with palate 0.89 6.71* 0.55
[0.46,1.73] [0.83,54.30] [0.26,1.16]
Number of non-cleft Malformations 1.60*** 1.53***
[1.26,2.04] [1.23,1.91]
Cesarean delivery 1.56 0.89 2.25
[0.58,4.23] [0.24,3.28] [0.72,6.98]
N 915 776 699 591 216 185
The Table reports the odds ratios for the effects of the intervention and baseline characteristics on mortality between the 7th and 28th day of life. 95%
Confidence intervals are in brackets. *, ** and *** indicate p < 0.1, < 0.05 and < 0.01, respectively.
Wehby et al. BMC Pediatrics 2011, 11:121
http://www.biomedcentral.com/1471-2431/11/121
Page 7 of 12Several factors had significant effects on hospitalization
days in the total sample, primarily due to effects on the
isolated CL/P group. Birth weight and gestational age
each reduced hospitalization days by about one day per
1000 grams and five gestational weeks, respectively.
Infants with cleft lip only and with cleft lip with palate in
the total sample had fewer hospitalization days by about
1.5 and 0.6 days, respectively, compared to infants with
cleft palate only. Also, infants born through cesarean
delivery had longer hospitalization by about one day.
Similar effects were seen on hospitalization in the iso-
lated group, in addition to a small decrease in hospitaliza-
tions for cases diagnosed prenatally (half a day on
average; marginally significant) and an increase in hospi-
talization days among those whose mothers had chronic
illnesses during pregnancy. (0.7 days on average).
Discussion
The study finds that early systematic pediatric care may
significantly reduce the neonatal morbidity of infants
with associated CL/P in South America who survive the
neonatal period, for whom the intervention reduced hos-
pitalization stay by about six days. This suggests that sys-
tematic pediatric care may significantly reduce inpatient
costs of associated cases. In the US, first year of life
healthcare costs for infants with associated CL/P exceed
those of unaffected children by more than 25 times [16].
As studies evaluate the effectiveness of primary preven-
tion programs for CL/P such as folic acid supplementa-
tion [33], tertiary prevention programs are essential for
reducing the health risks and economic burden of CL/P
for affected individuals and families. About half of the
neonatal hospital readmissions in the treatment group
were due to respiratory, weight loss, or feeding and nutri-
tion problems. This highlights the adverse oral-cleft
effects on early health and the importance of providing
adequate advice and training to parents before hospital
discharge after birth about optimal household approaches
to reduce these health problems, especially the feeding
problems.
There was a markedly larger benefit from the interven-
tion for reducing hospitalizations in the associated than
the isolated group. This is likely due to the greater health
needs and more frequent and longer hospitalizations
among the associated group that may be responsive to
the intervention. On average, infants in the associated
control group were hospitalized for about 10 days
between the 7
th and 28
th days of life, compared to about
2 days for the isolated control group. This highlights the
significantly elevated health problems among the asso-
ciated group. This differential effect between the isolated
and the associated group is consistent with the theory
that the intervention is more relevant on average for
infants with greater health needs that can be identified
and addressed by the intervention.
Congenital anomalies are a leading cause of neonatal
mortality and morbidity worldwide [34]. Despite substan-
tial progress in achieving the Millennium Development
Goals in reducing under-five mortality worldwide, there
has been far less improvement in neonatal mortality [34],
[35]. The study suggests that increasing access to systema-
tic pediatric care alone may not reduce the contribution of
congenital anomalies to neonatal mortality. A potential
contributor to this result is that CL/P impose a larger bur-
den on infant survival immediately after birth and during
the first few days of life during which infants typically are
hospitalized. After that, mortality risks drop significantly
in both the isolated and associated groups. About 62% and
76% of deaths in the isolated group occurred by the 7
th
and 8
th day of life, respectively. Similarly, 75% of deaths in
the associated group occurred by the 7
th day of life. The
study’s intervention began on the 7
th day of life given that
at-risk infants generally remain hospitalized during the
first few days of life and receive standard in-patient pedia-
tric care. Further, CL/P in the associated groups are asso-
ciated with major structural limitations and malformations
including cardiac and neural tube abnormalities that may
reduce the intervention effects on survival.
The study is among the first studies to estimate mortal-
ity rates among infants with CL/P in South America. The
results provide evidence that neonatal mortality and mor-
bidity are very high among infants with associated CL/P in
South America and that CL/P mortality rates are higher in
South American countries than the US [11-13]. Hujoel et
al (1992) report that neonatal mortality rates of infants
with CL/P in the state of Washington in 1984-1988 were
about 1.6% in the isolated group and 31.2% in the asso-
ciated group [13]. Druschel et al. (1996) report that first-
year mortality rates of infants with CL/P in New York
Table 6 Number of hospitalization days between 7
th and
28
th day among surviving infants and intervention
effects
Number of hospitalization
days
Intervention effect
Intervention Control Unadjusted Adjusted
Overall Sample 1.92
(4.73)
3.09 (6.19) -1.03**
(0.43)
-0.63*
(0.37)
Isolated 1.55
(4.41)
1.91 (4.61) -0.36
(0.40)
0.023
(0.26)
Associated 3.39
(5.64)
10.34 (9.11) -6.80***
(1.75)
-6.06***
(2.08)
The Table reports the average number of hospitalization days between the 7
th
and 28
th day of life in the intervention and control groups and the
intervention effects on hospitalization days. The unadjusted model includes
indicators for the country of birth as covariates. *, ** and *** indicate p < 0.1,
< 0.05 and < 0.01, respectively. The standard deviations of the number of
days hospitalized and the standard errors of the intervention effects are in
parentheses.
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Page 8 of 12Table 7 Effects of the Intervention and Baseline Characteristics on Hospitalization Days between the 7
th and 28
th Day
of Life
Total Sample Isolated Sample Associated Sample
Study intervention group -1.03** -0.63* -0.36 0.023 -6.80*** -6.06***
(0.43) (0.37) (0.40) (0.26) (1.75) (2.08)
Bolivia 0.18 -0.032 0.45 -0.30 7.67*** 17.7**
(0.77) (0.56) (0.58) (0.33) (2.15) (8.63)
Brazil -0.42 -0.14 -0.73* -0.28 -0.54 -0.47
(0.63) (0.64) (0.41) (0.42) (1.05) (3.03)
Chile -0.53 -0.49 -0.15 -0.24 -3.51*** -3.79**
(0.91) (0.69) (0.84) (0.48) (1.05) (1.61)
Colombia -1.41*** -1.33*** -0.90* -0.96*** -2.40 -3.40**
(0.52) (0.33) (0.50) (0.19) (1.85) (1.54)
Ecuador -1.39** -0.36 -0.82* -0.34 -2.89 0.17
(0.58) (0.59) (0.45) (0.41) (1.99) (5.53)
Venezuela -1.80*** -1.21*** -1.48*** -1.00*** -2.87 -1.07
(0.66) (0.43) (0.37) (0.23) (2.87) (2.98)
Maternal age (years) -0.028 -0.026 0.14
(0.022) (0.019) (0.10)
Number of prenatal visits 0.022 0.048 0.029
(0.044) (0.035) (0.26)
Maternal chronic illnesses 0.76 0.72* -0.95
(0.46) (0.41) (1.54)
African ancestry -0.19 -0.34 2.86
(0.43) (0.28) (3.13)
Native ancestry 0.49 0.42 0.66
(0.66) (0.47) (2.72)
Prenatal diagnosis of cleft -0.24 -0.48* -0.69
(0.52) (0.29) (2.11)
Associated status 2.16**
(1.05)
Birth weight (gm) -0.0009*** -0.00079*** -0.000056
(0.00029) (0.00024) (0.0019)
Gestational age (weeks) -0.21*** -0.13*** -0.52
(0.072) (0.050) (0.42)
Female -0.016 0.11 -0.99
(0.31) (0.22) (1.29)
Multiple birth -2.30** -1.00
(1.10) (0.70)
Cleft lip only -1.51*** -1.33*** -1.95
(0.37) (0.25) (3.25)
Cleft lip with palate -0.63* -0.53* -0.33
(0.36) (0.31) (2.13)
Number of non-cleft Malformations 0.27 0.72
(0.23) (0.54)
Cesarean delivery 0.81** 0.65* -0.049
(0.38) (0.34) (1.18)
N 772 660 638 543 134 117
The Table reports the effects of the intervention and baseline characteristics on hospitalization days between the 7
th and 28
th day of life. *, ** and *** indicate p
< 0.1, < 0.05 and < 0.01, respectively. The standard errors are in parentheses.
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Page 9 of 12State between 1983 and 1991 were about 1% in the iso-
lated group and 23.5% in the associated group [11].
The study finds significant ethnic disparities in neona-
tal mortality of infants with CL/P in South America, with
significantly higher risks among infants with African and
Native ethnic ancestry compared to other ancestries.
Racial disparities in infant health outcomes have been
documented in several of the study countries [36], con-
sistent with the study findings. For example, neonatal
and infant mortality rates in Brazil are twice as high
among children of black or mixed race women as whites
[37]. Identifying and targeting the contributing factors is
needed for reducing disparities. Cleft lip with/without
palate, lower birth weight, shorter gestational age and the
presence of multiple malformations besides CL/P are
additional risk factors for neonatal mortality risk that can
be routinely evaluated to identify infants with CL/P who
are at higher mortality risks. The greater mortality risk
among cases with cleft lip compared to cleft palate alone
is surprising, especially in the case of cleft lip alone. It is
unclear what factors are driving this result. It is possible
that cleft lip may be associated with greater parental
stress and anxiety in the neonatal period compared to
cleft palate alone, which may have adverse effects on the
infant’s household environment and care. More research
is needed to identify the reasons for this increase in mor-
tality risks.
One study limitation is the use of a non-randomized
control group. As mentioned above, the investigators
considered randomization to be unethical. However, the
similarity between the study intervention and control
groups on most baseline characteristics supports the uti-
lity of identifying a natural control group born in a very
close period to the intervention group in the same com-
munities when randomization is infeasible. Furthermore,
adjusting for the relevant baseline characteristics is
expected to account for any differences between the two
groups that may bias the treatment effect estimates.
The study provides an intervention model and
research design that may be implemented in other stu-
dies to evaluate the effects of early systematic pediatric
care on the neonatal survival and health of infants born
with other common and burdensome birth defects. Such
birth defects include neural tube defects, congenital
heart anomalies and Down Syndrome which also have
high mortality and morbidity especially in less developed
countries [38].
Conclusion
The study finds that early systematic pediatric care sig-
nificantly reduces neonatal hospitalization days for
infants with associated CL/P who survive the neonatal
period. Given the large health returns, the reduced hos-
pitalization costs and the low cost of providing systema-
tic pediatric care, improving the access of these infants
t os y s t e m a t i cp e d i a t r i cc a r ep r o g r a m si sl i k e l yt ob ea
cost-effective public policy intervention, although a for-
mal evaluation of the cost-effectiveness of the study’s
intervention is needed to accurately compare the added
health value to the costs at the population-level. Future
studies are needed to assess whether the effects of early
systematic pediatric care may vary by socioeconomic,
clinical and demographic characteristics, and to identify
the effects of such care beyond the neonatal period.
Such studies will identify infant groups who may benefit
most from pediatric care in order to design cost-effec-
tive policies and interventions to improve access to and
supply of pediatric care, and to maximize the returns of
these initiatives. Focused interventions are particularly
needed in resource-constrained environments such as in
the study countries. Other studies have found larger
prenatal care effects on birth weight among pregnancies
with higher fetal health risks [39]. Pediatric care may be
more effective in the groups with the largest mortality
and morbidity risks through identifying and addressing
the higher risk factors.
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